Interest costs add to Swissray loss
A big jump in sales for the year didn't help digital x-ray developer Swissray International, which posted a large net loss for its 1998 fiscal year (end-June). The New York City-based company indicated that it sustained a net loss of $22.5 million for
A big jump in sales for the year didn't help digital x-ray developer Swissray International, which posted a large net loss for its 1998 fiscal year (end-June). The New York City-based company indicated that it sustained a net loss of $22.5 million for the year, compared with a $13.7 million net loss in 1997. Swissray's 1998 sales were $22.9 million, compared with $13.2 million the previous year.
Swissray attributed its net loss to an increase in interest expenses resulting from convertible debentures issued for financing reasons. The firm also incurred significant expenses for its ddR Multi-System product and spent R&D cash for Tahoma TMSSM, a new healthcare asset management software offering.
The company's 74% increase in net sales was in part due to Swissray's purchase of Empower and Service Support Group. Empower was later sold to E.M. Parker. Swissray also enjoyed rising sales under its Philips OEM agreement, and the company sold four ddR Multi-Systems during fiscal year 1998.
The financial results released in December were part of the company's 10-K filing, the submission of which had been delayed by the company. In October, the NASDAQ stock exchange cited the company's failure to file its year-end results on time as part of the reason it was delisted. Swissray executives claimed that the firm's delay was due to the hiring of a new accountant firm, PricewaterhouseCoopers, and the time required to prepare the report (SCAN 11/11/98).
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
